Industry News

      Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies

      BOSTON & TORONTO--(BUSINESS WIRE)--Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a contract development and...

      Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

      BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of...

      Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute

      EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license...

      Out of Control: U.S. Employers Spend $245B a Year on Diabetes as Diagnosis Rates Rise, New Nomi Health Data Shows

      OREM, Utah--(BUSINESS WIRE)--Diabetes costs U.S. employers approximately $245 billion a year — more than double what the entire American automotive industry is worth, according...

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.